UPDATE: Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Dupixent (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration Jun 19, 2020 01:51PM
FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration Jun 19, 2020 01:51PM
FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration Jun 19, 2020 01:44PM
Regeneron (REGN) Reports Positive Phase 1 REGN1979 Data at ASH Dec 3, 2018 08:52AM
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Dec 1, 2018 12:00PM
View Older Stories

Oct 22, 2018 07:03AM Regeneron (REGN) Announces FDA Approves Asthma Indication for Dupixent
Oct 22, 2018 07:00AM FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 22, 2018 06:06AM Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Asthma Indication for Dupixent (dupilumab)
Oct 19, 2018 05:59PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:58PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA approves asthsma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 8, 2018 06:05PM Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Sep 28, 2018 04:46PM Regeneron (REGN), Sanofi (SNY) Report Approcal of Libtayo (cemiplimab), the First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 28, 2018 04:41PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:40PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:40PM FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:39PM FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Oct 16, 2017 08:06AM Sanofi (SNY), Regeneron (REGN) Phase 2 Study Results for Dupilumab Shows Significant Improvement Versus Placebo
Oct 16, 2017 08:01AM Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 16, 2017 08:00AM Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 11, 2017 08:00AM Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Oct 5, 2017 12:33PM Sanofi (SNY) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:31PM Regeneron (REGN) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:29PM Sanofi : Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Sep 28, 2017 05:56AM Sanofi (SNY) & Regeneron (REGN) Report Approval of Dupixent (Dupilumab) in European Union to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Sep 28, 2017 01:00AM Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 28, 2017 01:00AM Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 18, 2017 05:40AM Sanofi (SNY) & Regeneron Pharmaceuticals (REGN) Report Positive Study Results for Dupixent (Dupilumab)
Sep 16, 2017 02:15AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:15AM Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 11, 2017 06:12AM Regeneron (REGN) & Sanofi (SNY) Report Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 11, 2017 01:00AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 11, 2017 12:58AM Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sep 8, 2017 05:41AM Regeneron (REGN) & Sanofi (SNY) Granted FDA Breakthrough Designation for Cemiplimab (REGN2810), Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 01:00AM Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 12:58AM Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
Aug 25, 2017 08:00AM Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Jul 21, 2017 07:32AM Sanofi (SNY) and Regeneron (REGN) Receive Positive CHMP Opinion for Dupixent to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jun 27, 2017 05:47AM Sanofi (SNY) & Regeneron (REGN) Granted EU Marketing Approval from Kevzara (sarilumab) in Combination with Methotrexate
Jun 27, 2017 01:00AM Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 27, 2017 01:00AM Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 12, 2017 05:53AM Sanofi (SNY) & Regeneron (REGN) Presents Positive Results on Praluent (alirocumab) for Patients with Diabetes & Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:00AM Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 5, 2017 06:28AM Regeneron (REGN) & Sanofi (SNY) Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at ASCO Meetings
Jun 4, 2017 10:00AM Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4, 2017 10:00AM Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2017 05:52PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:47PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
View Older Stories